Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus

IDrugs

Volumn 12, Issue 12, 2009, Pages 785-798

  Colado, Joaquim ^a,b  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLUCOSIDE; HEMOGLOBIN A1C; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2;

ABNORMAL SENSATION; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTACT DERMATITIS; DIURESIS; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ECCHYMOSIS; ERYTHEMA; FACE SWELLING; FATIGUE; FLANK PAIN; GENITAL TRACT INFECTION; GLUCOSURIA; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; HYPOTENSION; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PALLOR; PATENT; PRURITUS; RASH; REVIEW; SIDE EFFECT; TREATMENT INDICATION; UPPER ABDOMINAL PAIN; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 71249152353     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. +-glucose contransporters, may provide a novel approach to treating diabetes. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T et al DIABETES 1999 48 9 1794-1800
2. 756936 Bristol-Myers Squibb and AstraZeneca announce worldwide collaboration to develop and commercialize diabetes compounds. Bristol-Myers Squibb Co PRESS RELEASE 2007 January 11
3. 757301 AstraZeneca and Bristol-Myers Squibb announce worldwide collaboration to develop and commercialise diabetes compounds. AstraZeneca plc PRESS RELEASE 2007 January 07
4. 757337 NCT00357370: A pilot study of BMS-512148 in subjects with type 2 diabetes. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2006
5. 759014 Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M J PHARMACOL EXP THER 2007 320 1 323-330
6. 806803 Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Whaley J, Hagan D, Taylor J, Xin L, Han S, Meng W, Ellsworth B, Sher P, McCann P, Wu G, Biller S et al DIABETES 2007 56 Suppl 1 Abs 0559-P
7. 809572 Dapagliflozin (BMS-512148), a selective inhibitor of the sodium-glucose uptake transporter 2 (SGLT2), reduces fasting serum glucose and glucose excursion in type 2 diabetes mellitus patients over 14 days. Komoroski B, Brenner E, Li L, Vachharajani N, Kornhauser D DIABETES 2007 56 Suppl 1 Abs 0188-OR
8. 810872 SGLT-2 inhibitor, a novel treatment for diabetes/obesity has shown positive proof of concept. Tanabe Seiyaku Co Ltd PRESS RELEASE 2007 June 08
9. 818319 Synthesis, SAR and evaluation of C-aryl glucosides as sodium-glucose cotransporter inhibitors for the treatment of type 2 diabetes. Meng W, Washburn WN, Ellsworth BA, Girotra RN, McCann PJ, Deshpande PP, Pullockaran AJ, Patel M, Sher PM, Wu G, Biller SA et al AM CHEM SOC NATL MEET EXPOSITION 2007 234 Abs Medi-57
10. 817916 Synthesis and characterization of dapagliflozin, a potent selective SGLT2 inhibitor for treatment of diabetes. Washburn WN, Meng W, Ellsworth BA, Nirschl A, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Biller SA, Deshpande PP et al AM CHEM SOC NATL MEET EXPOSITION 2007 234 Abs Medi-28
11. 821702 Management of type 2 diabetes: The role of incretin mimetics. Stonehouse AH, Holcombe JH, Kendall DM EXPERT OPIN PHARMACOTHER 2006 7 15 2095-2105
12. 914931 Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes. List JF, Woo VC, Villegas EM, Tang W, Fiedorek FT DIABETES 2008 57 Suppl 1 Abs 329-OR
13. 941628 Dapagliflozin-induced glucosuria is accompanied by weight loss in type 2 diabetes patients. Woo V, List JF, Morales E, Tang W, Fiedorek FT DIABETOLOGIA 2008 51 Suppl 1 Abs 796
14. 942139 Pooled population PK modeling for dapagliflozin in patients with type 2 diabetes mellitus. Feng Y, Zhang LP, Pfister M J CLIN PHARMACOL 2008 48 9 Abs 70
15. 942155 Exposure-efficacy outcome modeling for dapagliflozin, an orally selective SGLT2 inhibitor, in patients with type 2 diabetes. Feng Y, Zhang LP, List JF, Pfister M J CLIN PHARMACOL 2008 48 9 Abs 69
16. 947678 Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Saydah SH, Fradkin J, Cowie CC JAMA-J AM MED ASSOC 2004 291 3 335-342
17. 958498 Discovery of dapagliflozin: A potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R et al J MED CHEM 2008 51 5 1145-1149 •• Describes the synthesis of dapagliflozin. In vitro studies characterized dapagliflozin as a highly selective and potent human SGLT2 inhibitor, while in vivo experiments in the streptocozin-induced diabetic rat model revealed effectiveness as a glucose-lowering agent. These findings, together with a favorable ADME profile, prompted the development of dapagliflozin as a potential agent for the treatment of T2DM.
18. 958502 Population pharmacokinetic analysis of dapagliflozin in healthy and subjects with type 2 diabetes mellitus. Feng Y, Zhang L, Komoroski B, Pfister M CLIN PHARMACOL THER 2008 83 Suppl 1 Abs PIII-71
19. 958505 Safety, pharmacokinetics, and pharmacodynamics of dapagliflozin (BMS-512148) in an ascending, placebo-controlled, multiple-dose study in healthy adult subjects. Brenner E, Komoroski B, Boulton D, Li L DIABETOLOGIA 2007 50 Suppl 1 Abs 0765
20. 958506 Safety, pharmacokinetics, and pharmacodynamics of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, in an ascending, placebo-controlled, single-dose study in healthy adult subjects. Li L, Komoroski B, Boulton D, Brenner E, Vachharajani N, Kornhauser D DIABETOLOGIA 2007 50 Suppl 1 Abs 0764
21. 958507 Dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, inhibits glucose resorption and reduces fasting glucose in patients with type 2 diabetes mellitus. Komoroski B, Brenner E, Li L DIABETOLOGIA 2007 50 Suppl 1 Abs 0763
22. 965247 Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. Ellsworth BA, Meng W, Patel M, Girotra RN, Wu G, Sher PM, Hagan DL, Obermeier MT, Humphreys WG, Robertson JG, Wang A et al BIOORG MED CHEM LETT 2008 18 17 4770-4773
23. 969174 Bristol-Myers Squibb and AstraZeneca announce expansion of worldwide collaboration to develop and commercialize dapagliflozin in Japan. Bristol-Myers Squibb Co PRESS RELEASE 2008 December 08
24. 990350 Kissei: R&D pipeline. Kissei Pharmaceutical Co Ltd COMPANY WORLD WIDE WEB SITE 2009 January 31
25. 995565 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group DIABETES 1995 44 11 1249-1258
26. 1000452 NCT00643851: An efficacy & safety study of BMS-512148 in combination with metformin extended release tablets. Bristol-Myers Squibb Co; AstraZeneca plc CLINICALTRIALS.GOV 2008
27. 1007584 Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M CLIN PHARMACOL THER 2009 85 5 513-519 •• Reports the first use of dapagliflozin in patients with established T2DM, in a phase IIa, 14-day clinical trial. Dapagliflozin induced dose-dependent increases in glucosuria of up to 70 g/day, and ameliorated glycemic parameters including decreases in FPG and serum glucose as determined by an oral glucose tolerance test. Symptomatic vulvovaginal mycotic infections appeared to be more prevalent in dapagliflozin-treated arms, and occasional hypoglycemic episodes occurred in individuals who were also receiving metformin.
28. 1007588 Dapagliflozin, a novel SGLT2 inhibitor, induces dosedependent glucosuria in healthy subjects. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M CLIN PHARMACOL THER 2009 85 5 520-526 • In a series of single- and multiple-ascending-dose clinical trials performed in healthy individuals, dapagliflozin exhibited pharmacokinetic parameters that were compatible with once-daily dosing. At the highest dose tested, dapagliflozin inhibited the resorption of ? 50% of the filtered glucose, leading to a glucose excretion of 50 to 60 g/day -significantly less than that observed in the most severe forms of familial renal glucosuria. Therefore, dapagliflozin was unable to completely inhibit SGLT2.
29. 1013503 Dapagliflozin pilot study in insulin-resistant T2DM patients. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT DIABETES 2009 58 Suppl 1 Abs 482-P
30. 1013549 Dapagliflozin was not observed to prolong the QTc in a thorough QT/QTc study. Carlson GF, Tou CKP, Parikh S, Birmingham BK, Butler K DIABETES 2009 58 Suppl 1 Abs 483-P
31. 1018664 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group LANCET 1998 352 9131 837-853
32. 1029738 AstraZeneca presentation. AstraZeneca plc 2ND QUARTER REPORT 2009 July 30
33. 1031896 Bristol-Myers Squibb: In the pipeline. Bristol-Myers Squibb Co COMPANY WORLD WIDE WEB SITE 2009 July 31
34. 1042657 Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes List JF,Woo VC,Villegas EM,Tang W,Fiedorek FT DIABETES 2008 57 suppl. 1 Abs 329-OR
35. 1042659 Dapagliflozin-induced glucosuria is accompanied by weight loss in type 2 diabetes patients. List JF, Woo VC, Villegas EM, Tang W, Fiedorek FT DIABETES 2008 57 Suppl 1 Abs 461-P
36. 1042660 Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Han SP, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM DIABETES 2008 57 6 1723-1729 • Single doses of dapagliflozin increased glucosuria in both wild-type and ZDF rats, with reductions of plasma glucose AUC levels after a glucose challenge in wild-type rats, as well as in ZDF rats. Chronic administration of once-daily dapagliflozin for 2 weeks maintained efficacy in lowering FPG levels in ZDF rats and also enhanced insulin sensitivity in liver, but not in fat or skeletal muscle, as revealed by hyperinsulinemic-euglyemic clamp procedures.
37. 1042661 The SGLT2 inhibitor dapagliflozin prevents the disruption of pancreatic islet morphology in the high fat-fed-female ZDF rat. Peel JE, Macdonald RF, Westgate L, Jones HB, Poucher SM, Mayers RM, Whaley J DIABETOLOGIA 2009 52 Suppl 1 Abs 72
38. 1042662 The SGLT2 inhibitor dapagliflozin prevents the loss of pancreatic function in the high fat fed female (HFFF) ZDF rat. Macdonald RF, Westgate L, Poucher SM, Mayers RM, Whaley JM DIABETES 2009 58 9 Abs 1468-P
39. 1042663 Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. List JF, Woo V, Morales E, Tang W, Fiedorek FT DIABETES CARE 2009 32 4 650-657 •• In a 12-week pilot study, patients with recently diagnosed T2DM were randomized to one of five dapagliflozin doses, metformin or placebo. Improvements in all glucose parameters were observed in the dapagliflozin cohorts, including reductions in HbA1c, PPG and FPG, with dose-dependency reported only for FPG. Importantly, significant weight reductions were also reported in the dapagliflozin-treated patients compared with those receiving placebo. Hypoglycemic events were similar across all groups, but more genital infections occurred in the dapagliflozin-treated groups.
40. 1042670 Dapagliflozin prevents the development of diabetes in male ZDF rats. Zinker BA, Xin L, Cai H, Boehm S, Cap M, Zalaznick J, Washburn WN, Han S, Whaley JM DIABETOLOGIA 2009 52 Suppl 1 Abs 11
41. 1042671 Dapagliflozin improves glycaemic control in insulin-resistant patients with type 2 diabetes. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT DIABETOLOGIA 2009 52 Suppl 1 Abs 170
42. 1042672 Dapagliflozin as an add-on to metformin lowers hyperglycaemia in type 2 diabetes patients inadequately controlled with metformin alone. Bailey CJ, Gross JL, Bastone L, Bastien A, List JF DIABETOLOGIA 2009 52 Suppl 1 Abs 169
43. 1042676 Dapagliflozin mechanism of action in type 2 diabetes mellitus: Characterization of biomarker response. Feng Y, Kasichayanula S, Leslie B, List J, Zhang L, Pfister M CLIN PHARMACOL THER 2009 85 Suppl 1 Abs PI-21
44. 1042678 Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes. List JF, Woo V, Morales E, Tang W, Fiedorek FT DIABETOLOGIA 2008 51 Suppl 1 Abs 40
45. 1046811 Dapagliflozin study demonstrated significantly improved glycemic control and weight reduction in type 2 diabetes patients inadequately controlled with metformin. Bristol-Myers Squibb Co; AstraZeneca plc PRESS RELEASE 2009 October 02
46. 1047657 A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. DIABETES CARE 2009 32 9 1656-1662
47. 1047940 FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato A, Spinas GA, Halban PA et al PROC NATL ACAD SCI USA 2002 99 12 8236-8241
48. 1048009 b-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E DIABETES 2002 51 1 66-72
49. 1048556 Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: Brief overview. Melander A DIABETES 2004 53 Suppl 3 S151-S155
50. 1048564 Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Goodarzi MO, Bryer-Ash M DIABETES OBESITY METAB 2005 7 6 654-665
51. 1048565 Thiazolidinediones. Yki-Jarvinen H N ENGL J MED 2004 351 11 1106-1118
52. 1048568 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P et al N ENGL J MED 2008 358 24 2560-2572
53. 1048572 The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. Kanai Y, Lee WS, You G, Brown D, Hediger MA J CLIN INVEST 1994 93 1 397-404
54. 1048574 Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. Rossetti L, Smith D, Shulman GI, Papachristou D, Defronzo RA J CLIN INVEST 1987 79 5 1510-1515
55. 1048576 Molecular analysis of the SGLT2 gene in patients with renal glucosuria. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S et al J AM SOC NEPHROL 2003 14 11 2873-2882
56. 1048578 Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, Rueff J KIDNEY INT 2006 69 5 852-855
57. +-glucose cotransporters. Wright EM AM J PHYSIOL - RENAL PHYSIOL 2001 280 1 F10-F18
58. +/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Martin MG, Turk E, Lostao MP, Kerner C, Wright EM NAT GENET 1996 12 2 216-220
59. 1048581 Molecular basis for glucose-galactose malabsorption. Wright EM, Turk E, Martin MG CELL BIOCHEM BIOPHYS 2002 36 2-3 115-121
60. 1048582 Phlorizin: A review. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J DIABETES-METAB RES REV 2005 21 1 31-38
61. 1048583 Characterization of monocarboxylate transport in human kidney HK-2 cells. Wang Q, Lu Y, Yuan M, Darling IM, Repasky EA, Morris ME MOL PHARMACEUTICS 2006 3 6 675-685
62. 1048612 Long-term outcome of renal glucosuria type 0: The original patient and his natural history. Scholl-Burgi S, Santer R, Ehrich JH NEPHROL DIAL TRANSPLANT 2004 19 9 2394-2396
63. 1048617 Twenty-one additional cases of familial renal glucosuria: Absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ et al NEPHROL DIAL TRANSPLANT 2008 23 12 3874-3879
64. 1048618 Targeting prandial hyperglycemia: How important is it and how best to do this? Monnier L, Colette C CURR DIABETES REP 2008 8 5 368-374
65. 1048620 Standards of medical care in diabetes -2008. ADA DIABETES CARE 2008 31 Suppl 1 S12-S54
66. 1048724 Diabetes atlas. International Diabetes Federation INTERNET SITE 2009 October 09
67. 1049480 Johnson & Johnson: Selected pharmaceuticals in late stage US and EU development or registration as of October 13, 2009. Johnson & Johnson COMPANY WORLD WIDE WEB SITE 2009 October 13
68. 1049535 Effects of intensive glucose lowering in type 2 diabetes. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL et al N ENGL J MED 2008 358 24 2545-2559
69. 1049875 The effect of dapagliflozin, a highly selective SGLT-2 inhibitor on body weight in diet-induced obese rats. Devenny J, Harvey S, Rooney S, Godonis H, Washburn W, Whaley J, Taylor S, Pelleymounter MA OBESITY 2007 15 Suppl 9 Abs 384-P
70. 1050334 Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B DIABETOLOGIA 2009 52 1 17-30
71. 1051517 Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, Nakamura T et al AM J HUM GENET 2008 83 6 744-751
72. 1051520 Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ et al HYPERTENSION 2003 42 6 1206-1252 (Pubitemid 37553153)
73. Lack of pharmacokinetic interaction between dapagliflozin and pioglitazone in healthy subjects. Li T, Roche J, Zhang W, Pfister M, Liu X, Usansky H, Maurer C, Shyu W J CLIN PHARMACOL 2009 49 9 Abs 12